Kinfo
Creative Medical Technology Holdings Inc. logo

Creative Medical Technology Holdings Inc.

CELZNASDAQHealthcare·US · USD
$1.24
+0.04 (+3.33%)
Prices as of August 13, 2026 · market closed

Price

Key statistics

Valuation
Market cap8.17M USD
Enterprise value-626.06K USD
Trailing P/E2.81
Forward P/E-1.41
PEG ratio-0.05
Price / sales2,724.92
Price / book0.93
Profitability
Gross margin0.00%
Operating margin-208004.40%
Profit margin63.43%
Return on assets-47.32%
Return on equity-77.88%
Income (TTM)
Revenue3.00K USD
Gross profit2.01K USD
EBITDA-6.13M USD
Net income-6.04M USD
Diluted EPS-$2.11
Rev. growth (YoY)-100.00%
Balance sheet
Total cash8.84M USD
Total debt14.19K USD
Debt / equity0.16
Current ratio12.91
Book value / share$1.33
Cash flow (TTM)
Operating cash flow-5.90M USD
Levered free cash flow-3.45M USD
Shares & price
Shares outstanding3.70M
Float6.12M
Held by institutions3.44%
Beta0.00
50-day MA$1.33
200-day MA$2.03
52-week high$6.25
52-week low$0.62
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-07-0.39-0.41−5.13%2026-05-08-0.39-0.38+2.56%2026-03-20-0.37-0.80−116.22%2026-02-260.320.34+6.25%2025-11-07-0.48-0.48+0.00%
About Creative Medical Technology Holdings Inc.

Creative Medical Technology Holdings Inc. is a clinical- and commercial-stage biotechnology company specializing in regenerative medicine and immunotherapy. The company focuses on stem cell–based therapies addressing unmet needs across orthopedics, endocrinology, immunology, urology, and gynecology. Its pipeline includes proprietary platforms such as Olastrocel, a leading allogeneic cell therapy candidate for chronic lower back pain and metabolic indications, as well as ImmCelz, a personalized immune cell technology designed to modulate immune responses. Creative Medical Technology Holdings Inc. also develops and commercializes procedures and products for sexual health and infertility, including applications for erectile dysfunction, female sexual dysfunction, and premature ovarian failure. Headquartered in Phoenix, Arizona and founded in 1998, the company operates through multiple cell-based platforms using adult and perinatal stem cell technologies, aiming to deliver clinically validated regenerative treatments to patients via physician networks and specialized clinical programs.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Timothy Warbington
Employees
4
Headquarters
Phoenix, AZ, United States

Frequently asked questions about Creative Medical Technology Holdings Inc.